We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+29.52%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.72B
AUM Growth
+$775M
Cap. Flow
-$10.2M
Cap. Flow %
-0.22%
Top 10 Hldgs %
24.37%
Holding
169
New
21
Increased
56
Reduced
46
Closed
14

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$54.7M
2
EAR
Eargo, Inc. Common Stock
EAR
+$37.9M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$37.2M
4
SPRB
Spruce Biosciences
SPRB
+$36M
5
LUNG icon
Pulmonx
LUNG
+$24.5M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$135M
2
CNC icon
Centene
CNC
+$37.5M
3
BAX icon
Baxter International
BAX
+$27.2M
4
ASMB icon
Assembly Biosciences
ASMB
+$24.1M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 92.97%
2 Consumer Staples 1.52%
3 Consumer Discretionary 0.76%
4 Industrials 0.46%
5 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$1.81B
$56M 1.19%
328,750
-16,750
-5% -$2.48M
MRSN
27
DELISTED
Mersana Therapeutics
MRSN
$54.9M 1.16%
82,547
+7,130
+9% +$3.96M
TFX icon
28
Teleflex
TFX
$5.89B
$53.5M 1.13%
130,000
– –
EW icon
29
Edwards Lifesciences
EW
$53B
$53.1M 1.13%
582,000
– –
ALXN
30
DELISTED
Alexion Pharmaceuticals
ALXN
$47.9M 1.02%
306,750
+81,750
+36% +$10.5M
ALLK
31
DELISTED
Allakos
ALLK
$47.8M 1.01%
341,500
+99,918
+41% +$10.4M
PHR icon
32
Phreesia
PHR
$769M
$46.1M 0.98%
850,000
+50,000
+6% +$2.15M
HZNP
33
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$45.7M 0.97%
625,000
-25,000
-4% -$1.86M
KYMR icon
34
Kymera Therapeutics
KYMR
$9.03B
$44.3M 0.94%
713,865
+3,900
+0.5% +$190K
CNC icon
35
Centene
CNC
$32.9B
$43.8M 0.93%
730,000
-590,000
-45% -$37.5M
SGEN
36
DELISTED
Seagen Inc. Common Stock
SGEN
$43.8M 0.93%
250,000
– –
ALNY icon
37
Alnylam Pharmaceuticals
ALNY
$29B
$43.5M 0.92%
335,000
-4,814
-1% -$643K
EHC icon
38
Encompass Health
EHC
$12.5B
$41.3M 0.88%
628,500
-248,886
-28% -$14.6M
IMVT icon
39
Immunovant
IMVT
$8.24B
$41.2M 0.87%
891,000
+148,551
+20% +$6.87M
EAR
40
DELISTED
Eargo, Inc. Common Stock
EAR
$40.3M 0.86%
+45,000
New +$37.9M
INSP icon
41
Inspire Medical Systems
INSP
$1.73B
$40.1M 0.85%
213,350
-22,650
-10% -$3.7M
SPRB
42
Spruce Biosciences
SPRB
$127M
$39.6M 0.84%
+21,747
New +$36M
ASND icon
43
Ascendis Pharma A/S
ASND
$16.8B
$38.9M 0.83%
233,500
– –
ADPT icon
44
Adaptive Biotechnologies
ADPT
$4.05B
$37.5M 0.8%
635,000
– –
CVET
45
DELISTED
Covetrus, Inc. Common Stock
CVET
$36.9M 0.78%
1,285,000
+60,000
+5% +$1.62M
ACHC icon
46
Acadia Healthcare
ACHC
$2.96B
$35.2M 0.75%
700,000
-60,000
-8% -$2.39M
LUNG icon
47
Pulmonx
LUNG
$97.9M
$34.5M 0.73%
+500,000
New +$24.5M
HCAT icon
48
Health Catalyst
HCAT
$127M
$34.2M 0.72%
785,000
+82,000
+12% +$3.02M
ARDX icon
49
Ardelyx
ARDX
$997M
$33.3M 0.71%
5,148,112
+71,245
+1% +$423K
NKTX icon
50
Nkarta
NKTX
$176M
$33.3M 0.71%
541,000
+127
+0% +$5.28K
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Rock Springs Capital Management held 169 positions worth $4.72B, up 20% from $3.94B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management's Q4 2020 filing shows 21 new, 56 increased, 46 reduced and 14 closed positions. Its largest new stake was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M. The largest sale was Immunomedics Inc, an estimated $135M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2020 buy was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M.
  • Rock Springs Capital Management added most to Agios Pharmaceuticals in Q4 2020, an estimated $37.2M increase.
  • Rock Springs Capital Management's biggest Q4 2020 reduction was Centene, cutting an estimated $37.5M.
  • Rock Springs Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $135M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $4.72B portfolio in Q4 2020.
  • Rock Springs Capital Management opened 21 new positions and closed 14 in Q4 2020.
  • Rock Springs Capital Management's portfolio value rose 20% quarter-over-quarter to $4.72B.

Based on Rock Springs Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.